	US 11,718,861 B2
	Cancer immunotherapy by delivering class II MHC antigens using a VLP-replicon
Deb K. Chatterjee, Potomac, MD (US); and Stanislaw J. Kaczmarczyk, Frederick, MD (US)
Assigned to The USA, as represented by the Secretary, Dept. of Health and Human Services, Bethesda, MD (US)
Filed by THE USA as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed on Dec. 14, 2020, as Appl. No. 17/120,497.
Application 17/120,497 is a division of application No. 15/104,785, abandoned, previously published as PCT/US2014/070552, filed on Dec. 16, 2014.
Claims priority of provisional application 61/916,394, filed on Dec. 16, 2013.
Prior Publication US 2021/0163988 A1, Jun. 3, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/86 (2006.01); A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61K 45/06 (2006.01); C12N 7/00 (2006.01)

CPC C12N 15/86 (2013.01) [A61K 39/0011 (2013.01); A61K 39/001117 (2018.08); A61K 39/001124 (2018.08); A61K 39/001129 (2018.08); A61K 39/001144 (2018.08); A61K 39/001152 (2018.08); A61K 39/001163 (2018.08); A61K 39/001181 (2018.08); A61K 39/001182 (2018.08); A61K 39/001191 (2018.08); A61K 39/001194 (2018.08); A61K 39/12 (2013.01); A61K 45/06 (2013.01); C12N 7/00 (2013.01); A61K 2039/5258 (2013.01); A61K 2039/53 (2013.01); A61K 2039/585 (2013.01); C12N 2740/11023 (2013.01); C12N 2740/11042 (2013.01); C12N 2770/36123 (2013.01); C12N 2770/36134 (2013.01); C12N 2770/36143 (2013.01); C12N 2770/36145 (2013.01); C12N 2770/36152 (2013.01); C12N 2770/36171 (2013.01); C12N 2800/24 (2013.01); C12N 2810/6081 (2013.01)]

10 Claims

1. A pharmaceutical composition comprising a virus like particle (VLP), the VLP comprising:

a. an alphavirus replicon comprising a recombinant polynucleotide, wherein the polynucleotide comprises:

(i) a sequence encoding both subunits of a human class II major histocompatibility (MHC) antigen, and

(ii) a sequence encoding a costimulatory signal protein selected from the group consisting of CD80, CD28, CD86, and CTLA-4;

b. a retroviral gag protein, and

c. a fusogenic envelope protein,

wherein the VLP does not contain an alphavirus structural protein gene, wherein the VLP is not cytopathic to a eukaryotic cell.